Raymond T Bartus
Overview
Explore the profile of Raymond T Bartus including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
2617
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chu Y, Bartus R, Manfredsson F, Olanow C, Kordower J
Brain
. 2020 Mar;
143(3):960-975.
PMID: 32203581
We performed post-mortem studies on two patients with advanced Parkinson's disease 8 and10 years following AAV2-neurturin (CERE120) gene therapy, the longest post-mortem trophic factor gene therapy cases reported to date....
2.
Gross S, Shim B, Bartus R, Deaver D, McEachin Z, Betourne A, et al.
Exp Neurol
. 2019 Nov;
323:113091.
PMID: 31678350
Neurotrophic factors as candidates for ALS therapeutics have previously been studied in the context of attempts to slow disease progression. For a variety of reasons, clinical trials of neurotrophic factors...
3.
Rotrosen J, Bartus R, Gershon S
Neuropsychopharmacology
. 2017 Nov;
42(13):2655.
PMID: 29123233
No abstract available.
4.
Bartus R, Johnson Jr E
Neurobiol Dis
. 2016 Apr;
97(Pt B):156-168.
PMID: 27063798
Over the past 25years, about 3 dozen clinical reports have been published regarding the safety and possible efficacy of neurotrophic factors in patients with various neurodegenerative diseases. This effort involved...
5.
Bartus R, Johnson Jr E
Neurobiol Dis
. 2016 Apr;
97(Pt B):169-178.
PMID: 27063797
The therapeutic potential of neurotrophic factors has been recognized for decades, with clinical trials in human neurodegenerative diseases extending back at least 25years. While improvements in clinical dosing paradigms have...
6.
Olanow C, Bartus R, Volpicelli-Daley L, Kordower J
Mov Disord
. 2016 Jan;
30(13):1715-24.
PMID: 26769457
Trophic factors show great promise in laboratory studies as potential therapies for PD. However, multiple double-blind, clinical trials have failed to show benefits in comparison to a placebo control. This...
7.
Marks Jr W, Baumann T, Bartus R
Hum Gene Ther
. 2015 Dec;
27(7):522-7.
PMID: 26711317
The objective of this study was to assess the long-term safety of surgically administered recombinant adeno-associated virus serotype-2 (rAAV2)-neurturin (NRTN) to patients with advanced Parkinson's disease. Publications from prior trials...
8.
9.
Bartus R, Betourne A, Basile A, Peterson B, Glass J, Boulis N
Neurobiol Dis
. 2015 Oct;
85:11-24.
PMID: 26459114
Amyotrophic lateral sclerosis (ALS) is a chronic and progressive neuromuscular disease for which no cure exists and better treatment options are desperately needed. We hypothesize that currently approved β2-adrenoceptor agonists...
10.
Olanow C, Bartus R, Baumann T, Factor S, Boulis N, Stacy M, et al.
Ann Neurol
. 2015 Jun;
78(2):248-57.
PMID: 26061140
Objective: A 12-month double-blind sham-surgery-controlled trial assessing adeno-associated virus type 2 (AAV2)-neurturin injected into the putamen bilaterally failed to meet its primary endpoint, but showed positive results for the primary...